Investigational drug · Phase 2
XH-S003
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "XH-S003"
First trial start
2024
Dec 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XH-S003", any sponsor or status.
Conditions studied
As listed on its trial records.
- PNH - Paroxysmal Nocturnal Hemoglobinuria
- IgA Nephropathy
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "XH-S003" as an intervention, largest first.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT05946876 · 77 participants · Start Aug 24, 2023 · Primary completion Jul 11, 2024
Drug: XH-S003 (A) · For: Healthy
Sites: Adelaide, Australia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT06272747 · 36 participants · Start Jul 10, 2023 · Primary completion Jul 30, 2024
Drug: XH-S003; Placebo · For: Healthy Adults
Sites: Beijing, China
- A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal HemoglobinuriaEnrolling by invitation
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07657052 · 26 participants (planned) · Start Aug 15, 2025 · Primary completion Sep 30, 2029
Drug: XH-S003 Capsule · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT06978699 · 26 participants · Start May 21, 2025 · Primary completion Jan 21, 2026
Drug: XH-S003 Capsule; XH-S003 Capsule and 1 more · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07634744 · 25 participants · Start Dec 31, 2024 · Primary completion Apr 23, 2026
Drug: XH-S003 Capsule · For: IgA Nephropathy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for PNH - Paroxysmal Nocturnal Hemoglobinuria
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.